Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Medivir Selects Neuropathic Pain Candidate | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Medivir Selects Neuropathic Pain Candidate

Cathepsin S inhibitor to enter non-clinical development

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Medivir AB has selected MIV-247 as a candidate drug (CD) from its cathepsin S inhibitor project for the treatment of neuropathic pain. The CD will enter non-clinical development.

MIV-247 is a potent and highly selective inhibitor of cathepsin S. Cathepsin S has been shown to be an enzyme that is important for the maintenance of the neuropathic pain state, through its action in releasing fractalkine (a pro-inflammatory protein) in areas of the spinal cord important for pain sensation. Compounds from Medivir’s cathepsin S inhibitor project, including MIV-247, have shown good efficacy in experimental models of neuropathic pain, with no evidence of tolerance induction in longer-term studies.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics